265 related articles for article (PubMed ID: 24719428)
1. HIV-1 protease-substrate coevolution in nelfinavir resistance.
Kolli M; Ozen A; Kurt-Yilmaz N; Schiffer CA
J Virol; 2014 Jul; 88(13):7145-54. PubMed ID: 24719428
[TBL] [Abstract][Full Text] [Related]
2. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate.
Kolli M; Lastere S; Schiffer CA
Virology; 2006 Apr; 347(2):405-9. PubMed ID: 16430939
[TBL] [Abstract][Full Text] [Related]
3. Within-host co-evolution of Gag P453L and protease D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1 case.
Shibata J; Sugiura W; Ode H; Iwatani Y; Sato H; Tsang H; Matsuda M; Hasegawa N; Ren F; Tanaka H
Antiviral Res; 2011 Apr; 90(1):33-41. PubMed ID: 21338625
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.
Kolli M; Stawiski E; Chappey C; Schiffer CA
J Virol; 2009 Nov; 83(21):11027-42. PubMed ID: 19706699
[TBL] [Abstract][Full Text] [Related]
5. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
[TBL] [Abstract][Full Text] [Related]
6. Sequence variability in p6 gag protein and gag/pol coevolution in human immunodeficiency type 1 subtype F genomes.
Rossi AH; Rocco CA; Mangano A; Sen L; Aulicino PC
AIDS Res Hum Retroviruses; 2013 Jul; 29(7):1056-60. PubMed ID: 23458243
[TBL] [Abstract][Full Text] [Related]
7. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
Su CT; Kwoh CK; Verma CS; Gan SK
J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
9. Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease.
Özen A; Lin KH; Kurt Yilmaz N; Schiffer CA
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):15993-8. PubMed ID: 25355911
[TBL] [Abstract][Full Text] [Related]
10. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
[TBL] [Abstract][Full Text] [Related]
11. Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors.
Codoñer FM; Peña R; Blanch-Lombarte O; Jimenez-Moyano E; Pino M; Vollbrecht T; Clotet B; Martinez-Picado J; Draenert R; Prado JG
Sci Rep; 2017 Jun; 7(1):3717. PubMed ID: 28623276
[TBL] [Abstract][Full Text] [Related]
12. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
Bally F; Martinez R; Peters S; Sudre P; Telenti A
AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
[TBL] [Abstract][Full Text] [Related]
15. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
[TBL] [Abstract][Full Text] [Related]
16. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
17. The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.
Bandaranayake RM; Kolli M; King NM; Nalivaika EA; Heroux A; Kakizawa J; Sugiura W; Schiffer CA
J Virol; 2010 Oct; 84(19):9995-10003. PubMed ID: 20660190
[TBL] [Abstract][Full Text] [Related]
18. Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.
Kozísek M; Henke S; Sasková KG; Jacobs GB; Schuch A; Buchholz B; Müller V; Kräusslich HG; Rezácová P; Konvalinka J; Bodem J
Antimicrob Agents Chemother; 2012 Aug; 56(8):4320-30. PubMed ID: 22644035
[TBL] [Abstract][Full Text] [Related]
19. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
Prashar V; Bihani SC; Ferrer JL; Hosur MV
Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
[TBL] [Abstract][Full Text] [Related]
20. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]